Ab­b­Vie adds ul­cer­a­tive col­i­tis to Skyrizi la­bel

The FDA ap­proved Ab­b­Vie’s Skyrizi to treat mod­er­ate to se­vere ul­cer­a­tive col­i­tis, adding an­oth­er in­di­ca­tion to the im­munol­o­gy drug’s ar­se­nal.

Ab­b­Vie has said that UC …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.